Related Experiment Videos
[Chemotherapy after prostatectomy--effects of long term administration of Pivmecillinam (PMPC)]
Abstract:
The therapeutic efficacy of Pivmecillinam (PMPC) against urinary tract infections after prostatectomy was investigated. PMPC was orally administered at the dose of 300 mg/day for 2-14 weeks after initial intravenous postoperative chemotherapy with other antibiotics for 0-24 days (average 5.7 days). Thirty patients underwent retropubic prostatectomy and the other 59 patients received TUR-P. The chemotherapeutic efficacy for 19 patients who had over 10(3) CFU/ml of microorganisms was as follows: The effective rate was 48.4% after 2 weeks, 53.8% after 4 weeks, 66.7% after 5-6 weeks and 100% after 7-9 weeks. The prophylactic efficacy for 70 patients who had no or less than 10(3) CFU/ml of microorganisms was 64.3% after 2 weeks, 79.6% after 4 weeks, 86.7% after 5-6 weeks and 90.0% after 7-9 weeks. The overall clinical efficacy of PMPC for 89 patients was 60.7% after 2 weeks, 74.2% after 4 weeks, 83.3% after 5-6 weeks, 90.0% after 7-9 weeks and 100% after 10-14 weeks. No severe side effects were found in these 89 cases. In conclusion, PMPC is a useful drug for the long term treatment after prostatectomy.
Insights
Pivmecillinam (PMPC) effectively treats urinary tract infections following prostatectomy. This antibiotic showed good therapeutic and prophylactic efficacy with no severe side effects in patients.
Area of Science:
- Urology
- Infectious Diseases
- Pharmacology
Context:
- Urinary tract infections (UTIs) are a common complication after prostatectomy.
- Current treatment protocols often involve initial intravenous chemotherapy followed by oral agents.
- Long-term management strategies for post-prostatectomy UTIs require effective and safe oral antibiotics.
Purpose:
- To investigate the therapeutic and prophylactic efficacy of Pivmecillinam (PMPC) for managing UTIs in patients who have undergone prostatectomy.
- To evaluate the clinical outcomes of oral PMPC administration following initial intravenous antibiotic therapy.
Summary:
- This study assessed Pivmecillinam (PMPC) in 89 patients post-prostatectomy, with 19 receiving it for chemotherapy and 70 for prophylaxis.
- Oral PMPC (300 mg/day for 2-14 weeks) demonstrated increasing efficacy over time, reaching 100% in both groups by 7-14 weeks.
- No severe adverse events were reported, indicating a favorable safety profile.
Impact:
- Pivmecillinam (PMPC) presents a viable and safe option for long-term oral treatment of urinary tract infections after prostatectomy.
- The findings support the use of PMPC in clinical practice to improve patient outcomes and reduce UTI recurrence post-surgery.